Successful antibody screening study
Therapeutic antibody supplier MorphoSys and technology company Biametrics will continue their collaboration in the area of high-throughput antibody screening following a successful feasibility study.
Biametrics performed the screening study using MorphoSys’ reagents and its own microarray-based b-screen device, recently launched for high-throughput biomolecular interaction screening/analysis, for the characterisation of Fab fragment antigen interactions. The study demonstrated the advantages of b-screen to speed up the overall antibody screening process using the microarray format.
The b-screen device enables the detection of biomolecules in a high-density array format on microscope slide disposables. No fluorescence labels are needed for readout, which leads to minimised sample pre-treatment and reagent consumption. The optical detection method makes it possible to reduce the complexity of the conventional label-free assays while enhancing the throughput and maintaining precision and reliability.
“We have identified b-screen as a promising technology in the field of epitope mapping and will now broaden our collaboration with Biametrics,” said Dr Markus Enzelberger, Senior VP, Head of Discovery Alliances & Technologies at MorphoSys.
Novel 3D bioprinter can replicate human tissue
Biomedical engineers have invented a 3D printing system capable of fabricating structures that...
Medical gauze can identify shark species following attacks
Injury dressings found in first-aid kits can be used to identify shark species involved in bite...
Liquid biopsy analysis helps improve cancer monitoring
Researchers have developed a liquid biopsy method that sequences and analyses DNA fragments...
